| Autor: |
Dong H; Huiru Dong, Harvard University, Boston, Massachusetts., Stringfellow EJ; Erin J. Stringfellow, Harvard University., Russell A; Alton Russell, McGill University, Montreal, Québec, Canada., Jalali MS; Mohammad S. Jalali (msjalali@mgh.harvard.edu), Harvard University. |
| Jazyk: |
angličtina |
| Zdroj: |
Health affairs (Project Hope) [Health Aff (Millwood)] 2024 Sep; Vol. 43 (9), pp. 1319-1328. |
| DOI: |
10.1377/hlthaff.2023.01667 |
| Abstrakt: |
In the midst of the opioid crisis in the US, efforts to mitigate overdose risks have become paramount, leading some states to introduce mandates for coprescribing the life-saving overdose reversal drug naloxone. These mandates were designed to specifically address people receiving opioid analgesics who had an elevated risk for overdose. This included people receiving high opioid dosages, those concurrently using benzodiazepines, or those with a history of substance use disorder or overdose. Using a nationally representative, multipayer cohort of patients receiving prescription opioids, we investigated how naloxone codispensing rates changed at the state level from 2016 to 2021 among patients with an elevated risk for overdose. Then we used controlled interrupted time series analyses to assess mandates' longitudinal impact on naloxone codispensing in ten states that implemented mandates. We observed an immediate and significant increase in the naloxone codispensing rates in eight states after the implementation of mandates. Nevertheless, in five of these states, the codispensing rates exhibited a subsequent downward trend after the initial increase. State mandates show potential for improving naloxone codispensing; however, mandates alone might not be adequate for sustained change. Further research is needed to identify strategies complementing and enhancing the impact of mandates in combating the overdose crisis. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
